Coric has authored more than 65 peer-reviewed publications. He has served as president of the Connecticut Psychiatric Society. He previously served as the inpatient chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. Coric has also continued to serve as an Associate Clinical Professor of Psychiatry at Yale School of Medicine. During his career, he has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole partial dopamine agonist), Opdivo® (nivolumab anti-PD1), Yervoy® (Ipilimumab anti-CTLA-4), Daklinza® (daclatasvir NS5A inhibitor), and Sunvepra® (asunaprevir NS3 inhibitor). Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Coric has also led the expansion of Biohaven to international markets, including the formation of subsidiaries in Ireland and Asia-Pacific.ĭr. Today, Biohaven is an industry leader in the use of digital tools and technologies to increase patient engagement and enhance the success of its novel treatments. Coric has been instrumental in establishing Biohaven’s agile, digital-centric operating and commercial model. Coric led Biohaven’s acquisition of a novel Kv7 channel targeting platform - adding the latest advances in ion-channel modulation to Biohaven’s neuroscience portfolio.Ī proponent of innovation that extends beyond the R&D cycle to all aspects of pharmaceutical operations, Dr. These include epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA). The company’s focus on scientific innovation is evidenced in its broad therapeutic portfolio comprised of early- and late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, with little or no treatment options. Coric’s stewardship, Biohaven has focused on discovering, developing and commercializing life-changing therapies that address unmet medical needs. The pillars of the company’s success - Commitment to Patients, Winning with Science and Creating Shareholder Value - continue to be the foundation of Biohaven’s ongoing growth. Coric has positioned Biohaven on its new course continuing its growth trajectory, harnessing its proven drug development expertise, extensive portfolio of clinical-stage assets and robust discovery research capabilities. Coric spearheaded the acquisition of Biohaven by Pfizer in May 2022 for approximately $13 billion in total consideration.ĭr. Capitalizing on the extraordinary patient and shareholder value that Biohaven has built with Nurtec ODT and its CGRP franchise, Dr. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. Biohaven also received approval in Europe and other major markets - advancing its “treat and prevent” migraine therapy to the approximately one billion patients suffering from migraine across the world. A little more than one year later, Biohaven transformed the migraine treatment paradigm with the FDA approval of an expanded indication for Nurtec ODT for the preventive treatment of episodic migraine - becoming the first all-in-one migraine medication for the acute and preventive treatment of migraine. Coric successfully led the company through its first FDA approval and the launch of Nurtec® ODT (rimegepant CGRP receptor antagonist) for the acute treatment of migraine. His leadership translated into dramatic growth for the company, from its initial pre-money valuation of about $6M to the sale of the company for $13B in total considerations. Coric led the company in the pursuit of its bold vision from an entrepreneurial start-up into a modern, publicly traded company listed on the New York Stock Exchange with the mission of advancing novel medications to underserved patients. In his over seven years as CEO of Biohaven, Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |